Song Honglin, Cicek Mine S, Dicks Ed, Harrington Patricia, Ramus Susan J, Cunningham Julie M, Fridley Brooke L, Tyrer Jonathan P, Alsop Jennifer, Jimenez-Linan Mercedes, Gayther Simon A, Goode Ellen L, Pharoah Paul D P
CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK,
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Hum Mol Genet. 2014 Sep 1;23(17):4703-9. doi: 10.1093/hmg/ddu172. Epub 2014 Apr 12.
The aim of this study was to estimate the contribution of deleterious mutations in BRCA1, BRCA2, MLH1, MSH2, MSH6 and PMS2 to invasive epithelial ovarian cancer (EOC) in the population. The coding sequence and splice site boundaries of all six genes were amplified in germline DNA from 2240 invasive EOC cases and 1535 controls. Barcoded fragment libraries were sequenced using the Illumina GAII or HiSeq and sequence data for each subject de-multiplexed prior to interpretation. GATK and Annovar were used for variant detection and annotation. After quality control 2222 cases (99.2%) and 1528 controls (99.5%) were included in the final analysis. We identified 193 EOC cases (8.7%) carrying a deleterious mutation in at least one gene compared with 10 controls (0.65%). Mutations were most frequent in BRCA1 and BRCA2, with 84 EOC cases (3.8%) carrying a BRCA1 mutation and 94 EOC cases (4.2%) carrying a BRCA2 mutation. The combined BRCA1 and BRCA2 mutation prevalence was 11% in high-grade serous disease. Seventeen EOC cases carried a mutation in a mismatch repair gene, including 10 MSH6 mutation carriers (0.45%) and 4 MSH2 mutation carriers (0.18%). At least 1 in 10 women with high-grade serous EOC has a BRCA1 or BRCA2 mutation. The development of next generation sequencing technologies enables rapid mutation screening for multiple susceptibility genes at once, suggesting that routine clinical testing of all incidence cases should be considered.
本研究的目的是评估BRCA1、BRCA2、MLH1、MSH2、MSH6和PMS2基因中的有害突变对人群中浸润性上皮性卵巢癌(EOC)的影响。在2240例浸润性EOC病例和1535例对照的生殖系DNA中扩增了所有六个基因的编码序列和剪接位点边界。使用Illumina GAII或HiSeq对带条形码的片段文库进行测序,并在解读之前对每个受试者的序列数据进行解复用。使用GATK和Annovar进行变异检测和注释。经过质量控制后,最终分析纳入了2222例病例(99.2%)和1528例对照(99.5%)。我们发现193例EOC病例(8.7%)至少在一个基因中携带有害突变,而对照中有10例(0.65%)。BRCA1和BRCA2中的突变最为常见,84例EOC病例(3.8%)携带BRCA1突变,94例EOC病例(4.2%)携带BRCA2突变。在高级别浆液性疾病中,BRCA1和BRCA2联合突变患病率为11%。17例EOC病例在错配修复基因中携带突变,其中包括10例MSH6突变携带者(0.45%)和4例MSH2突变携带者(0.18%)。每10名高级别浆液性EOC女性中至少有1人携带BRCA1或BRCA2突变。下一代测序技术的发展使得能够同时快速筛查多个易感基因的突变,这表明应考虑对所有发病病例进行常规临床检测。